Lumanity Value, Access & Outcomes

Don't miss the poster currently on display at the International Society for Pharmacoepidemiology annual meeting, Characteristics of Patients with ATTR Amyloidosis and Methodological Approaches for Establishing Clinical Subtype in the Netherlands. #ICPE24 #epidemiology #pharmacoepidemiology #amyloidosis #ATTR #ISPEAnnual2024

Navigating the New EU HTA Regulation: Are You Prepared? Our experts are here to help you understand what this regulation means for your organization. Whether you're looking for bespoke training sessions for your team or need guidance on navigating these complex changes, we've got you covered. Visit our dedicated EU HTA regulation webpage to learn more and see how we can support your journey. Stay ahead of the curve—prepare now! https://buff.ly/3AwVvI6 #Training #HealthEconomics #HEOR

Navigating the market for new medical technology is challenging, and staying current with the evolving pharmaceutical and biotech landscape is crucial for success. Our experts lead the way in developing innovative solutions and understanding the impacts of changes like the new EU HTA Regulation and the US Inflation Reduction Act. We regularly share our insights and offer bespoke training to help your teams understand the complex path to market. Visit the Perspectives page on our website to read our latest insights and learn how we can illuminate the path to market for your health technology. https://buff.ly/3XeE9bQ #HealthEconomics #OutcomesResearch #HEOR #MarketAccess

If you're in Berlin at the International Society for Pharmacoepidemiology annual meeting, be sure to stop by exhibit booth 901, chat with our experts, and learn about some of our latest research. For the full list of our presentations at ICPE this week, visit https://buff.ly/3yQUFFO #ICPE24 #epidemiology #pharmacoepidemiology #healthcaredata #ISPEAnnual2024

The International Society for Pharmacoepidemiology annual meeting is underway in Berlin! Don't miss all of our oral presentations and posters, including: Oral Presentations: - Target Trial Emulation with Real World Evidence: Regulatory Grade Pharmacoepidemiology in the SIGMA consortium - GP consultation for menstrual disorders after COVID-19 vaccination – a self-controlled cohort study based on healthcare data from the Netherlands - Impact of data source diversity on the distribution of key variables in cohorts of pregnancies extracted with the ConcePTION algorithm leveraging on a random forest imputation model - Unravelling Sex Disparities in Statin Dose Titration Patterns in Primary Care Posters: - Interim results from the VAC4EU Post-Authorization Safety Study (PASS) among recipients of the Pfizer-BioNTech COVID-19 (Comirnaty®) vaccine in Europe - Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European Healthcare Data: Methods and Results of the Second Study Feasibility Assessment - Migration background and HbA1c Checks and Balances: a large routine care data study in the Netherlands - Readiness of electronic healthcare record data sources for rapid evaluation of safety signals of SARS-CoV-2 Vaccines in Europe: results from the Covid-19 Vaccine Monitoring project - Challenges of multi-country post-authorisation safety studies for surveillance of new medical products - Oral antihypertensives in hypertensive pregnancy and the association with fetal growth: a population-based cohort study - Characteristics of Patients with ATTR Amyloidosis and Methodological Approaches for Establishing Clinical Subtype in the Netherlands - Rates of SARS-CoV-2 breakthrough infection or severe COVID-19 and associated risk factors after primary and booster vaccination against COVID-19 in the Netherlands - Identifying and profiling patients with heart failure in a population-based cohort through linkage of primary and secondary care data - Factor XA Inhibitor-related major bleeding events in the Netherlands - Use of SGLT2 Inhibitors in Patients With Type 2 Diabetes and Chronic Kidney Disease – a Multi-Country Report from the FOUNTAIN Platform - Exploring sources of statistical heterogeneity in a multi-database observational study: results from a case study using EXACOS-CV Connect with our staff while in Berlin, including Eline Houben, Jetty Overbeek, Josine Kuiper, Naomi Boxall, Eleonora Iob, PhD, and Nikita Jeswani, and don't forget to stop by exhibit booth 901! Learn more about the conference and the program agenda at https://buff.ly/4cBDJ3J #ICPE2024 #pharmacoepidemiology #epidemiology #RWE #RWD #SafetyStudies #Amyloidosis #SIGMAConsortium #ISPEAnnual2024

Defining a “clinically distinct” target population and addressing the limitations of trial evidence are just two challenges manufacturers face when demonstrating the value of drugs for treating rare diseases. Our whitepaper explores seven key challenges in this area and offers practical approaches to overcome them. Read it now to learn more: https://buff.ly/4dpMyiw #LumanityPerspectives #HTA #HEOR #RareDiseases

Why should stakeholder engagement sit at the heart of your value communication strategy? In our view, we explore how engaging your internal stakeholders will help you to develop coherent and concise evidence-based messaging that ensures alignment among your affiliates. Click here to read our view: https://buff.ly/4fQ7nFA #LumanityPerspectives #HEOR #HTA #ValueCommunications #StakeholderEngagement

We're proud to be a Gold sponsor and an exhibitor at the annual International Society for Pharmacoepidemiology meeting this week! Be sure to connect with our staff on site, including Eline Houben, Jetty Overbeek, Josine Kuiper, Naomi Boxall, Eleonora Iob, PhD, and Nikita Jeswani, and don't miss all of our presentations, including 1 workshop, two oral presentations, and 10 posters! Reach out to our on-site staff or stop by booth 901 during the conference. See you soon! #ICPE24 #epidemiology #pharmacoepidemiology #RWE #RWD #healthcaredata

Navigating the market for new medical technology is challenging, and staying current with the evolving pharmaceutical and biotech landscape is crucial for success. Our experts lead the way in developing innovative solutions and understanding the impacts of changes like the new EU HTA Regulation and the US Inflation Reduction Act. We regularly share our insights and offer bespoke training to help your teams understand this complex path. Visit the Perspectives page on our website to read our latest insights and learn how we can illuminate the path to market for your health technology. https://buff.ly/3M5eXhT #HealthEconomics #OutcomesResearch #HEOR #MarketAccess

Joint Clinical Assessment (JCA) is a central component of the new European Union health technology assessment (EU HTA) Regulation, which will streamline HTA across EU member states and play a major role in bringing new medical technology to market. In our whitepaper Lumanity experts explore the challenges of JCA, with particular focus on oncology, rare disease and advanced therapy medicinal products (ATMPs). https://buff.ly/3YQtCF5 #LumanityPerspectives #HTA #JCA #HEOR #EUHTA